3 mg Sumatriptan Subcutaneous Injection for Migraine
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current sumatriptan subcutaneous injection products for treating migraines and cluster headaches have moderate to severe side effects, and there is a need for a newer strength of sumatriptan to reduce side effects and improve patient adherence.
Innovation Solution
A composition comprising an aqueous solution of sumatriptan or its pharmaceutically acceptable salts in an amount equivalent to 3 mg of sumatriptan base, combined with sodium chloride to maintain osmolality between 275 to 315 mOsm/kg, and administered subcutaneously to achieve specific plasma profiles and reduce side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current sumatriptan subcutaneous injection products (6 mg or 4 mg) are used for migraine treatment, then migraine relief is achieved, but moderate to severe side effects occur
Solution Approach 1:
The patent changes the dosage parameter from conventional 4-6 mg to a lower 3 mg dose, while simultaneously optimizing formulation parameters including osmolality (275-315 mOsm/kg), pH (4.2-5.3), and the ratio of sumatriptan to sodium chloride (0.80:1.00 to 1.40:1.00). These parameter changes enable achieving effective migraine relief with reduced side effects by delivering the active ingredient at an optimized concentration that balances efficacy and tolerability.
2Reliability
If higher strength sumatriptan products are used, then migraine efficacy is improved, but side effects and patient non-adherence increase
Solution Approach 1:
The patent optimizes the concentration and formulation parameters of sumatriptan to create a 3 mg subcutaneous injection product. By carefully controlling the osmolality, pH, and excipient ratios, the formulation achieves optimal bioavailability and therapeutic effect at this lower dose, thereby improving patient adherence while maintaining efficacy.
Solution Approach 2:
The patent creates a new sumatriptan formulation that replicates the therapeutic effectiveness of higher strength products (6 mg or 4 mg) but with reduced side effect profile. The optimized 3 mg formulation with specific osmolality and pH characteristics serves as an alternative that copies the efficacy while improving tolerability, thereby increasing patient adherence.
3Ease of operation
If sumatriptan dose is reduced to lower side effects, then patient adherence improves, but systemic exposure may be insufficient
Solution Approach 1:
The patent compensates for the reduced 3 mg dose by optimizing formulation parameters including osmolality (275-315 mOsm/kg), pH (4.2-5.3), and the sumatriptan-to-sodium-chloride ratio (0.80:1.00 to 1.40:1.00). These parameter changes enhance the bioavailability and absorption efficiency of sumatriptan, ensuring adequate systemic exposure (Cmax: 35-57 ng/ml, AUC0-2: 30-50 ng.hr/ml, AUC0-inf: 43-70 ng.hr/ml) despite the lower dose, thereby maintaining efficacy while improving adherence.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The subcutaneous administration of the sumatriptan composition results in a systemic exposure characterized by Cmax of 35 ng/ml to 57 ng/ml, AUC0-2 of 30 ng.hr/ml to 50 ng.hr/ml, and AUC0-inf of 43 ng.hr/ml to 70 ng.hr/ml, which is equivalent to or greater than that achieved by an equivalent dose of commercially available sumatriptan, while reducing side effects.
Implementation Method 1
sodium chloride in an amount to maintain the osmolality of said solution between 275 to 315 mOsm/kg
Implementation Method 2
The therapeutic activity of sumatriptan for the treatment of migraine is thought to be due to the agonist effects at the 5-HT 1B/1D receptors on intracranial blood vessels (including the arterio-venous anastomoses) and sensory nerves of the trigeminal system, which result in cranial vessel constriction
Implementation Method 3
inhibition of pro-inflammatory neuropeptide release through nerve endings in the trigeminal system
Data Source
AI summary
The present application relates to a method of treating migraine or cluster headache in a human patient, said method comprising administering subcutaneously composition comprising sumatriptan or its pharmaceutically acceptable salt, in an amount equivalent to 3 mg sumatriptan base.